During the past decade, US Oncology conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 9 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 7 clinical trials were completed. i.e. 70% of trials that started reached the finish line.

Out of the total clinical trials conducted in "US Oncology" #1 sponsor was "Eli Lilly and Company" with 18 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Celgene" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "Loxo Oncology, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "US Oncology" #1 collaborator was "ARMO BioSciences" with 3 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "US Oncology" are "Breast Neoplasms" (4 trials), "Neoplasm Metastasis" (4 trials), "Breast Cancer" (3 trials), "Metastatic Breast Cancer" (3 trials) and "Non Small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "US Oncology" in a lesser frequency.

Most popular intervention types in "US Oncology" are "Drug" (25 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (9 trials), "Placebo" (7 trials), "Exemestane" (3 trials), "Fulvestrant" (3 trials) and "Pegilodecakin" (3 trials). Other intervention names were less common.

The vast majority of trials in "US Oncology" are 18 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "US Oncology". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in US Oncology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in US Oncology, 6 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".